Cabotamig

N/A

Report date: 2026/03/19 17:01:33

Base Information

Drug NameCabotamig
Drug Alias NameARB-202
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionCadherin-17 modulatorsAnti-CD3
TargetsCadherin-17T cell surface glycoprotein CD3
Therapy Area/IndicationsEsophageal adenocarcinomaPancreatic NeoplasmsLiver Neoplasms +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaHong Kong
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesArbele Corp
China Registration ClassN/A

Develop Information

Active CompaniesArbele Corp
Inactive CompaniesN/A
Active IndicationsEsophageal adenocarcinomaPancreatic NeoplasmsLiver Neoplasms +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A